- Estimated Enrollment:250
- Study Start Date:February 2013
- Estimated Study Completion Date:June 2017
- Estimated Primary Completion Date:April 2017 (Final data collection date for primary outcome measure)
Catalyst
Slingshot members are tracking this event:
Mallinckrodt (MNK) to complete Phase 3 Study of Hydromorphone HCl by Intrathecal Administration Using a Programmable Implantable Pump
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| MNK |
|
|
||||
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Apr 17, 2018
Occurred Source:
https://clinicaltrials.gov/ct2/show/NCT01709721
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 3 Study, Hydromorphone Hcl, Hydromorphone, Intrathecal Administration, Chronic Pain, Implantable Pump, Two-arm
